Supporting Information

Rh^{III}-Catalyzed One-Pot Cascade Synthesis of Quinazolines with *N*-Alkoxyamide as an Amidating Reagent

Hui-Bei Xu,^a Yan-Ying Zhu,^a Jia-Hui Yang,^a Xin-Yue Chai,^a Lin Dong^{*a}

1.	General methods	2
2.	General procedure for the C–H activation/amidation/annulation cascade	2
3.	Synthetic application of 3	2
4.	Mechanism study	3
5	Characterization data for compounds	5
6	¹ H and ¹³ C NMR spectra	.12

1. General methods

NMR data were obtained for ¹H at 400 MHz or 600 MHz, and for ¹³C at 100 MHz or 151MHz. Chemical shifts were reported in ppm from tetramethylsilane with the solvent resonance as the internal standard in CDCl₃ solution. ESI HRMS was recorded on a Waters SYNAPT G2 and Water XEVO G2 Q-ToF. UV detection was monitored at 220 nm. TLC was performed on glass-backed silica plates. Column chromatography was performed on silica gel (200-300 mesh), eluting with ethyl acetate and petroleum ether. *N*-methoxybenzamide **1a**¹ and aryl imidate **2**² were prepared according to the literature procedures.

2. General procedure for the C-H activation/amidation/annulation cascade

Ethyl benzimidate **1** (0.15 mmol), *N*-methoxybenzamide **2** (0.1 mmol), $[Cp*RhCl_2]_2$ (1.5 mg, 2.5 mol%), AgBF₄ (1.9 mg, 10 mol%) were stirred in DCE (1 mL) under an Ar atmosphere at 120 °C for 3 h. After completion, the reaction mixture was purified by flash chromatography eluting with ethyl acetate and petroleum ether (1:15) to give the product **3** as an off-white solid.

3. Synthetic application of 3



4-Ethoxy-2-phenylquinazoline **3a** (0.2 mmol, 50 mg) was dissolved in EtOH (6 mL). Hydrochloric acid (3 mL, 35%) was slowly added to the solution. The reaction was heated at 100 °C for one hour. After cooling down to room temperature and concentrating in vacuum, the mixture was washed with saturated aqueous sodium bicarbonate and extracted by DCM (3×15 mL). The organic phase was combined and dried over magnesium sulphate. The solvent was removed under reduced pressure to give 2-phenylquinazolin-4(3H)-one **5** without further purification as white solid (40 mg, 90%).



To a mixture of 2-phenylquinazolin-4(3H)-one **5** (0.1 mmol, 22.2 mg) and thionyl chloride (0.2 mmol, 24 mg) 8μ L of dimethylformamide (0.5 mL) was slowly added. The mixture was heated at 50 °C for 2 hours. After cooling down to room temperature the mixture was washed with saturated aqueous sodium bicarbonate and extracted by DCM (3×15 mL). The organic phase was combined, dried and purified through column chromatography to afford the pure product **6** as yellow solid (18.3 mg, 76%).



A mixture of 2-phenylquinazolin-4(3*H*)-one (0.1 mmol), $[Ru(p-cymene)Cl_2]_2$ (5 mol %), AgSbF₆ (20 mol %) and AdCO₂H (0.2 mmol, 2.0 equiv) was taken in a 15-mL pressure tube. To this reaction mixture, DCE (0.5 mL) and the corresponding allyl acetate (0.5 mmol) were added via micro syringe and the closed reaction mixture was allowed to stir at 130 °C for 10 min. After completion as indicated by TLC, the reaction mixture was cooled to ambient temperature. Further the reaction mixture was diluted with dichloromethane and washed with 1N NaOH solution to neutralize the excess acid and dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by column chromatography using ethyl acetate/hexane as eluent to afford the desired isoquinolino[1,2-b]quinazolinone product 7 (17.5 mg, 67%).

4. Mechanism study

4.1 Intermolecular competition experiment



To a tube with a stir bar was added benzimidates (2b, 0.15 mmol) and (2e, 0.15 mmol), *N*-methoxybenzamide 1a (0.10 mmol), $[Cp*RhCl_2]_2$ (3 mg), AgBF₄ (6 mg) were stirred in DCE (1 mL) at 120 °C for 3 h. After completion, the reaction mixture was purified by flash chromatography eluting with ethyl acetate and petroleum ether (1:15) to give the product 3ab and 3ae in 41% and 26% yield, respectively. The ratio of the products is 1.6:1, which revealed that electronic effect of benzimidates have slightly affected the reaction.

4.2 Deuterium-labeling experiment

Deuterium-labeling experiment was proceeded to investigate the mechanism of this reaction. Ethyl benzimidate **1a** was stirred in the absence of *N*-methoxybenzamide at 120 °C for 30 min under standard condition with AcOD/DCE, and the deuterium rate was obtained from ¹H NMR. This suggested that C–H bond activation could occur at the first step.





4.3 KIE experiments (parallel experiments)



Two Schlenk tubes each was charged with Ethyl benzimidate **2a** (0.075 mmol) or [**D**₅]-**2a** (0.075 mmol) and *N*-methoxybenzamide **1a** (0.05 mmol), [Cp*RhCl₂]₂ (5 mol%,), AgBF₄ (0.03 equiv), and DCE (0.5 mL). The reaction mixture was stirred at 120 °C for 1h under argon atmosphere. After rapidly evaporating the two mixtures solely, the product **3aa** and [**D**₄]-**3aa** were purified by flash column chromatography on silicagel (eluent:PE/EA = 15:1). The KIE value was determined to be $k_H/k_D = 2.4$ on the yield ratio of **3aa** and [**D**₄]-**3aa**, which indicated that the cleavage of the C–H bond is likely involved in the rate-limiting step.

5 Characterization data for compounds

4-ethoxy-2-phenylquinazoline (3aa)²



23.8mg (95%); off-white solid; mp = 109.3-113.1°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.59 (dd, *J* = 7.5, 2.2 Hz, 2H), 8.18 (dd, *J* = 8.1, 1.6 Hz, 1H), 8.01 (d, *J* = 8.4 Hz, 1H), 7.81 (ddd, *J* = 8.4, 6.9, 1.5 Hz, 1H), 7.51 (dt, *J* = 7.0, 4.4 Hz, 4H), 4.79 (q, *J* = 7.1 Hz, 2H), 1.58 (t, *J* = 7.1 Hz, 3H).¹³C NMR (101 MHz, Chloroform-*d*) δ 166.7, 160.1, 151.6, 138.1, 133.5,

130.5, 128.5, 128.4, 127.8, 126.3, 123.5, 115.4, 62.9, 14.4.

4-ethoxy-7-methyl-2-phenylquinazoline (3ab)²



22.7 mg (86%); off-white solid; mp = 92.3-93.5°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.74 – 8.41 (m, 2H), 8.05 (d, *J* = 8.3 Hz, 1H), 7.80 (s, 1H), 7.62 – 7.42 (m, 3H), 7.33 (dd, *J* = 8.3, 1.6 Hz, 1H), 4.77 (q, *J* = 7.1 Hz, 2H), 2.56 (s, 3H), 1.57 (t, *J* = 7.1 Hz, 3H).¹³C NMR (101 MHz, Chloroform-*d*) δ 166.6, 160.1, 152.0, 144.2, 138.3, 130.4,

128.4, 128.4, 128.3, 127.1, 123.2, 113.2, 62.7, 22.1, 14.4.

4-ethoxy-7-methoxy-2-phenylquinazoline (3ac)²



25.5 mg (91%); off-white solid; mp = 126.4-129.3°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.63 – 8.51 (m, 2H), 8.05 (d, *J* = 9.0 Hz, 1H), 7.55 – 7.45 (m, 3H), 7.35 (d, *J* = 2.5 Hz, 1H), 7.11 (dd, *J* = 9.0, 2.5 Hz, 1H), 4.75 (q, *J* = 7.1 Hz, 2H), 3.97 (s, 3H), 1.55 (t, *J* = 7.1 Hz, 3H).¹³C NMR (101 MHz, Chloroform-*d*) δ 166.4, 163.8,

160.8, 154.0, 138.2, 130.4, 128.5, 128.4, 124.8, 118.6, 109.7, 106.4, 62.7, 55.7, 14.5.



4-ethoxy-7-fluoro-2-phenylquinazoline (3ad)²

23.6 mg (88%); off-white solid; mp = 88.5-93.3°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.58 (dd, J = 6.8, 3.0 Hz, 2H), 8.19 (dd, J = 9.0, 6.1 Hz, 1H), 7.86 – 7.39 (m, 4H), 7.39 – 7.04 (m, 2H), 4.78 (q, J = 7.0

Hz, 2H), 1.57 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 167.1, 166.6, 164.6, 161.3, 130.8, 128.6, 128.5, 126.3, 126.2, 116.2 (d, J = 25 Hz), 112.3, 112.0 (q, J = 20 Hz), 111.9, 63.1, 14.4.

7-chloro-4-ethoxy-2-phenylquinazoline (3ae)²

22.7 mg (80%); off-white solid; mp = 104.0-108.7°C; ¹H NMR (400

OEt N

MHz, Chloroform-*d*) δ 8.56 (dd, J = 6.8, 3.0 Hz, 2H), 8.18 – 7.92 (m, 2H), 7.62 – 7.34 (m, 4H), 4.77 (q, J = 7.1 Hz, 2H), 1.57 (t, J = 7.1 Hz, 3H).¹³C NMR (101 MHz, Chloroform-*d*) δ 166.6, 161.2, 152.5, 139.6, 137.7, 130.8, 128.6, 128.4, 127.2, 127.0, 125.0, 113.7, 63.2, 14.4.

4-ethoxy-7-iodo-2-phenylquinazoline (3af)²



35.7 mg (95%); off-white solid; mp = 89.6-93.4°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.69 – 8.12 (m, 3H), 7.96 – 7.65 (m, 2H), 7.50 (dd, *J* = 5.0, 2.0 Hz, 3H), 4.76 (q, *J* = 7.1 Hz, 2H), 1.56 (t, *J* = 7.1 Hz, 3H).¹³C NMR (101 MHz, Chloroform-*d*) δ 166.8, 160.8, 152.4, 137.7, 136.8, 135.2, 130.8, 128.6, 128.5, 124.7, 114.4, 100.7, 63.2, 14.4.

methyl 4-ethoxy-2-phenylquinazoline-7-carboxylate (3ag)²



26.8 mg (87%); off-white solid; mp = 138.2-146.8°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.68 (d, J = 1.7 Hz, 1H), 8.63 – 8.52 (m, 2H), 8.21 (d, J = 8.4 Hz, 1H), 8.09 (dd, J = 8.5, 1.5 Hz, 1H), 7.51 (dd, J = 5.1, 2.0 Hz, 3H), 4.79 (qd, J = 7.1, 1.2 Hz, 2H), 4.01 (s, 3H), 1.58 (t, J = 7.1 Hz, 3H).¹³C NMR (101 MHz,

Chloroform-*d*) δ 166.6, 166.4, 160.8, 151.4, 137.7, 134.6, 130.8, 130.1, 128.6, 128.5, 125.9, 123.9, 117.8, 63.3, 52.6, 14.4.

4-ethoxy-2-phenyl-7-(trifluoromethyl)quinazoline (3ah)²



26.1 mg (82%); off-white solid; mp = 100.5-106.0°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.62 – 8.54 (m, 2H), 8.28 (dd, *J* = 5.0, 3.4 Hz, 2H), 7.68 (dd, *J* = 8.7, 1.6 Hz, 1H), 7.57 – 7.48 (m, 3H), 4.81 (q, *J* = 7.1 Hz, 2H), 1.59 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.9, 158.6, 151.5, 141.4, 133.7, 132.0 (d, *J* = 32

Hz), 128.7, 127.9, 126.9, 125.3 (q, J = 4 Hz), 124.2 (s, J = 270 Hz), 123.6, 115.5, 63.1, 14.4.

4-ethoxy-5-fluoro-2-phenylquinazoline (3ai)²



25.5 mg (95%); off-white solid; mp = 92.0-94.3°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.57 (dd, J = 6.7, 3.0 Hz, 2H), 7.85 – 7.76 (m, 1H), 7.72 (td, J = 8.1, 5.3 Hz, 1H), 7.51 (dd, J = 5.1, 2.0 Hz, 3H), 7.14 (ddd, J = 10.5, 7.8, 1.2 Hz, 1H), 4.80 (q, J = 7.1 Hz, 2H), 1.59 (t, J = 7.1 Hz, 3H).¹³C NMR (101 MHz, Chloroform-*d*) δ 165.8 (d, J = 5 Hz), 160.6 (d, J = 5)

= 2 Hz), 158.6 (d, *J* = 260 Hz), 153.8, 137.6, 133.3 (d, *J* = 10 Hz), 130.8, 128.5, 128.4, 123.8 (d, *J* = 5 Hz), 112.0 (d, *J* = 22 Hz), 106.0 (d, *J* = 12 Hz), 63.3, 14.3.

4-ethoxy-5-methyl-2-phenylquinazoline (3aj)²



18.2 mg (69%); off-white solid; mp = 76.3-80.9°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.59 (dd, J = 7.4, 2.4 Hz, 2H), 7.93 (d, J = 8.3 Hz, 1H), 7.65 (dd, J = 8.4, 7.2 Hz, 1H), 7.58 – 7.40 (m, 3H), 7.32 – 7.27 (m, 1H), 4.77 (q, J = 7.1 Hz, 2H), 2.86 (s, 3H), 1.58 (t, J = 7.1 Hz, 3H).¹³C NMR (101 MHz, Chloroform-*d*) δ 167.9, 159.3, 136.9, 133.0, 130.7, 129.0, 128.5, 128.4, 125.7, 114.9, 63.2, 23.9, 14.4.

4-ethoxy-6-methyl-2-phenylquinazoline (3ak)²



25.6 mg (97%); off-white solid; mp = 109.3-113.1°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.64 – 8.49 (m, 2H), 8.05 – 7.85 (m, 2H), 7.64 (dd, *J* = 8.5, 2.0 Hz, 1H), 7.57 – 7.46 (m, 3H), 4.78 (q, *J* = 7.1 Hz, 2H), 2.54 (s, 3H), 1.58 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.3, 159.3, 136.5, 135.5, 130.3, 128.4, 127.5, 122.5,

115.2, 62.8, 21.6, 14.5.

6-chloro-4-ethoxy-2-phenylquinazoline (3al)²



22.4 mg (79%); off-white solid; mp = 138.4-144.3°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.56 (dd, *J* = 6.7, 3.0 Hz, 2H), 8.13 (d, *J* = 2.4 Hz, 1H), 7.93 (d, *J* = 8.9 Hz, 1H), 7.73 (dd, *J* = 8.9, 2.4 Hz, 1H), 7.50 (dd, *J* = 5.1, 2.0 Hz, 3H), 4.77 (q, *J* = 7.1 Hz, 2H), 1.57 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 165.9, 160.3, 150.2,

137.7, 134.2, 131.8, 130.7, 129.5, 128.5, 128.4, 122.8, 116.0, 63.2, 14.4.

4-ethoxy-6-methoxy-2-phenylquinazoline (3am)



11.7 mg (42%); off-white solid; mp = 109.3-113.1°C; IR (cm⁻¹) *v*: 2982, 1622, 1584, 1438, 1348, 1210, 1158,1019, 768, 703. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.59 – 8.49 (m, 2H), 7.91 (d, *J* = 9.0 Hz, 1H), 7.47 (dtd, *J* = 24.1, 8.2, 2.5 Hz, 5H), 4.78 (q, *J* = 7.1 Hz, 2H), 3.95 (s, 3H), 1.58 (t, *J* = 7.1 Hz, 3H).¹³C NMR (101 MHz,

Chloroform-*d*) δ 165.8, 158.1, 157.8, 147.4, 138.3, 130.1, 129.4, 128.4, 128.1, 125.4, 115.8, 101.5, 62.8, 55.7, 14.5. HRMS: m/z (ESI) calcd for C₁₇H₁₇N₂O₂[M+H]⁺: 281.1285, found: 282.1281.

4-methoxy-2-phenylquinazoline (3an)



20.7 mg (88%); off-white solid; mp = 109.3-113.1°C; IR (cm⁻¹) *v*: 3058, 1620, 1557, 1501, 1444, 1375, 1103, 911, 759, 672. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.74 – 8.44 (m, 2H), 8.17 (d, *J* = 8.2 Hz, 1H), 8.05 (d, *J* = 8.4 Hz, 1H), 7.83 (t, *J* = 7.8 Hz, 1H), 7.52 (d, *J* = 6.9 Hz, 4H), 4.31 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 167.3, 160.0, 133.8, 130.9,

128.7, 128.5, 127.5, 126.7, 123.5, 115.2, 54.4. HRMS: m/z (ESI) calcd for $C_{15}H_{13}N_2O$ [M+H]⁺: 237.1022, found: 237.1026.

4-ethoxy-2-phenylthieno[2,3-d]pyrimidine (3ap)²



20.2 mg (79%); off-white solid; mp = 74.6-83.1°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.53 (dd, *J* = 7.6, 2.1 Hz, 2H), 7.84 (d, *J* = 5.4 Hz, 1H), 7.66 – 7.37 (m, 4H), 4.78 (q, *J* = 7.1 Hz, 2H), 1.55 (t, *J* = 7.1 Hz, 3H).¹³C NMR (101 MHz, Chloroform-*d*) δ 164.1, 162.7, 161.1, 137.8, 133.9, 130.3, 128.4, 128.3, 124.7, 115.9, 62.9, 14.5.

8-ethoxy-6-phenyl-[1,3]dioxolo[4,5-g]quinazoline (3aq) 23.8 mg (81%); off-white solid; mp = 56.2-62.1 °C; IR (cm⁻¹) *v*: 3066, 2976, 2921, 1620, 1573, 1497, 1324, 1105, 760, 680. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.50 (dd, *J* = 6.8, 3.0 Hz, 2H), 7.69 (d, *J* = 8.5 Hz, 1H), 7.40 (p, *J* = 3.5 Hz, 3H), 7.03 (d, *J* = 8.5 Hz, 1H), 6.18 (s, 2H), 4.67 (q, *J* = 7.1 Hz, 2H), 1.47 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.4, 160.4, 150.6, 140.4, 137.8, 130.7, 128.6, 128.3, 118.4, 111.4, 109.5, 102.8, 62.9, 14.4. HRMS: m/z (ESI) calcd for: C₁₇H₁₅N₂O₃[M+H]⁺:295.1083, found: 295.1084.

4-ethoxy-2-(p-tolyl)quinazoline (3ba)²



22.9 mg (87%); off-white solid; mp = 74.6-78.5 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.57 – 8.41 (m, 2H), 8.16 (ddd, J = 8.2, 1.6, 0.7 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.80 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.49 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 7.37 – 7.28 (m, 2H), 4.78 (q, J = 7.1 Hz, 2H), 2.44 (s, 3H), 1.57 (t, J = 7.1 Hz, 3H). ¹³C NMR (101

MHz, Chloroform-*d*) δ 166.6, 160.2, 151.7, 140.7, 135.4, 133.4, 129.2, 128.5, 127.7, 126.1, 123.5, 115.3, 62.8, 21.5, 14.4.

4-ethoxy-2-(4-methoxyphenyl)quinazoline (3ca)²



22.4 mg (80%); off-white solid; mp = 68.9-75.4 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.64 – 8.45 (m, 2H), 8.14 (dd, *J* = 8.1, 1.4 Hz, 1H), 7.96 (d, *J* = 8.5 Hz, 1H), 7.78 (ddd, *J* = 8.5, 6.9, 1.5 Hz, 1H), 7.47 (ddd, *J* = 8.0, 6.9, 1.1 Hz, 1H), 7.12 – 6.93 (m, 2H), 4.76 (q, *J* = 7.1 Hz, 2H), 3.89 (s, 3H), 1.57 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.6, 161.7, 159.9, 151.8, 133.4,

130.8, 130.1, 127.5, 125.9, 123.5, 115.1, 113.7, 62.8, 55.4, 14.4.

4-ethoxy-2-(4-(trifluoromethyl)phenyl)quinazoline (3da)²



25.7 mg (81%); off-white solid; mp = 124.8-128.7 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.75 – 8.61 (m, 2H), 8.19 (dd, *J* = 8.2, 1.4 Hz, 1H), 8.00 (d, *J* = 8.4 Hz, 1H), 7.84 (ddd, *J* = 8.5, 6.9, 1.5 Hz, 1H), 7.75 (d, *J* = 8.2 Hz, 2H), 7.55 (ddd, *J* = 8.1, 6.9, 1.2 Hz, 1H), 4.78 (q, *J* = 7.1 Hz, 2H), 1.59 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.9, 158.6, 151.5, 141.4, 133.7, 132.0 (d, *J*

= 30 Hz), 128.7, 127.9, 126.9, 125.3 (q, J = 3 Hz), 124.2 (q, J = 270 Hz), 123.6, 115.5, 63.1, 14.4.

4-ethoxy-2-(4-fluorophenyl)quinazoline (3ea)²



24.9 mg (93%); off-white solid; mp = 107.3-111.9 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.68 – 8.45 (m, 2H), 8.17 (dd, *J* = 8.2, 1.5 Hz, 1H), 7.99 (d, *J* = 8.4 Hz, 1H), 7.81 (ddd, *J* = 8.5, 6.9, 1.6 Hz, 1H), 7.51 (ddd, *J* = 8.1, 6.9, 1.2 Hz, 1H), 7.23 – 7.07 (m, 2H), 4.77 (q, *J* = 7.1 Hz, 2H), 1.58 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ

166.8, 164.6 (d, *J* = 250 Hz), 159.1, 151.5, 134.2 (d, *J* = 10 Hz), 133.6, 130.5 (d, *J* = 10 Hz), 127.6,



126.4, 123.6, 115.3 (d, *J* = 20 Hz), 63.0, 14.4.

2-(4-chlorophenyl)-4-ethoxyquinazoline (3fa)²

24.2 mg (86%); off-white solid; mp = 109.3-113.1°C; ¹H NMR (400

MHz, Chloroform-*d*) δ 8.63 – 8.43 (m, 2H), 8.16 (dd, J = 8.2, 1.4 Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.81 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.60 – 7.40 (m, 3H), 4.76 (q, J = 7.1 Hz, 2H), 1.57 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.77, 159.02, 151.61, 136.63, 133.57, 129.80, 128.59, 127.78, 126.52, 123.58, 115.35, 62.97, 14.4.

2-(4-bromophenyl)-4-ethoxyquinazoline (3ga)²



23.6 mg (72%); off-white solid; mp = 109.3-113.1°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.46 (d, *J* = 8.3 Hz, 2H), 8.17 (dd, *J* = 8.2, 1.4 Hz, 1H), 7.97 (d, *J* = 8.4 Hz, 1H), 7.81 (ddd, *J* = 8.4, 7.0, 1.4 Hz, 1H), 7.62 (d, *J* = 8.3 Hz, 2H), 7.56 – 7.46 (m, 1H), 4.76 (q, *J* = 7.1 Hz, 2H), 1.57 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.8,

159.1, 151.6, 137.1, 133.6, 131.6, 130.1, 127.8, 126.5, 125.2, 123.6, 115.4, 63.0, 14.4.

4-ethoxy-2-(4-ethoxyphenyl)quinazoline (3ha)

Br



21.2 mg (72%); off-white solid; mp = 102.5-109.7°C; IR (cm⁻¹) v:3070, 2980, 2936, 1601, 1573, 1421, 1326, 1249, 1153, 760, 659, 541. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.60 – 8.48 (m, 2H), 8.20 – 8.09 (m, 1H), 7.97 (d, *J* = 8.4 Hz, 1H), 7.78 (ddd, *J* = 8.4, 6.9, 1.5 Hz, 1H), 7.46 (ddt, *J* = 7.9, 6.8, 0.9 Hz, 1H), 7.08 – 6.94 (m, 2H), 4.84 – 4.68 (m, 2H), 4.12 (q, *J* = 7.0 Hz, 2H), 1.57 (t, *J* = 7.1 Hz,

3H), 1.46 (t, J = 7.0 Hz, 3H).¹³C NMR (101 MHz, Chloroform-*d*) δ 166.6, 161.2, 159.9, 151.6, 133.4, 130.5, 130.1, 127.4, 125.8, 123.5, 115.0, 114.2, 63.6, 62.8, 14.8, 14.4. HRMS: m/z (ESI) calcd. for [C₁₈H₁₉N₂O₂+H]⁺: 295.1447, found: 295.1447.

4-ethoxy-2-(o-tolyl)quinazoline (3ia)²



11.9 mg (45%); off-white solid; mp = 109.3-113.1°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.21 (ddd, J = 8.1, 1.5, 0.7 Hz, 1H), 8.00 (dt, J = 8.4, 0.9 Hz, 1H), 7.94 (dd, J = 7.4, 1.8 Hz, 1H), 7.83 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.55 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.33 (tdd, J = 8.7, 4.7, 2.2 Hz, 3H), 4.71 (q, J = 7.1 Hz, 2H), 2.65 (s, 3H), 1.54 (t, J = 7.1 Hz, 3H). ¹³C

NMR (101 MHz, Chloroform-*d*) δ 166.3, 163.1, 151.4, 138.7, 137.3, 133.4, 131.2, 130.5, 129.2, 127.8, 126.5, 125.8, 123.4, 114.7, 63.0, 21.4, 14.5.

4-ethoxy-2-(2-fluorophenyl)quinazoline (3ja)²



22.8 mg (85%); off-white solid; mp = 109.3-113.1°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.17 (td, J = 8.0, 4.4 Hz, 2H), 8.01 (d, J = 8.4 Hz, 1H), 7.86 – 7.76 (m, 1H), 7.57 – 7.49 (m, 1H), 7.43 (tdd, J = 7.5, 4.8, 1.8 Hz, 1H), 7.27 (t, J = 7.5 Hz, 1H), 7.20 (dd, J = 11.1, 8.2 Hz, 1H), 4.72 (q, J = 7.1 Hz, 2H), 1.54 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.6, 161.4 (d, J = 254 Hz), 158.8 (d, J = 5 Hz), 151.6, 133.5, 132.0, 131.9,

131.3 (d, *J* = 9 Hz), 128.0, 127.3 (d, *J* = 10 Hz), 126.81, 124.0 (d, *J* = 4 Hz), 123.47, 116.8 (d, *J* = 23 Hz), 115.1, 63.1, 14.4.

2-(2-chlorophenyl)-4-ethoxyquinazoline (3ka)²



20.4 mg (72%); off-white solid; mp = 80.9-87.5°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.23 (dd, J = 8.1, 1.4 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.98 – 7.80 (m, 2H), 7.59 (ddd, J = 8.1, 7.0, 1.0 Hz, 1H), 7.55 – 7.48 (m, 1H), 7.43 – 7.35 (m, 2H), 4.72 (q, J = 7.1 Hz, 2H), 1.54 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.6, 161.0, 151.1, 138.2, 133.7,

 $133.0,\,131.7,\,130.6,\,130.2,\,127.7,\,127.1,\,126.8,\,123.6,\,115.1,\,63.4,\,14.5.$

2-(2-bromophenyl)-4-ethoxyquinazoline (3la)²



14.4 mg (44%); off-white solid; mp = 90.8-95.8°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.23 (dd, J = 8.2, 1.4 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.91 – 7.75 (m, 2H), 7.71 (dd, J = 7.9, 1.2 Hz, 1H), 7.59 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.44 (td, J = 7.5, 1.2 Hz, 1H), 7.30 (td, J = 7.7, 1.8 Hz, 1H), 4.74 (q, J = 7.1 Hz, 2H), 1.54 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz,

Chloroform-*d*) δ 166.6, 161.8, 133.8, 133.8, 131.7, 130.4, 127.6, 127.4, 127.2, 123.6, 121.9, 115.1, 63.6, 14.5.

4-ethoxy-2-(m-tolyl)quinazoline (3ma)²



19.1 mg (72%); off-white solid; mp = 69.6-71.2°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, J = 9.2, 1.9 Hz, 2H), 8.17 (dd, J = 8.2, 1.4 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.81 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H), 7.50 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.35 – 7.27 (m, 1H), 4.79 (q, J = 7.1 Hz, 2H), 2.49 (s, 3H), 1.58 (t, J = 7.1 Hz, 3H). ¹³C

NMR (101 MHz, Chloroform-*d*) δ 166.7, 160.3, 151.7, 138.0, 133.4, 131.4, 129.0, 128.3, 127.8, 126.3, 125.7, 123.5, 115.3, 62.9, 21.6, 14.4.

2-(3-chlorophenyl)-4-ethoxyquinazoline (3na)²



25.6 mg (90%); off-white solid; mp = 78.9-84.1°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.56 (d, J = 2.1 Hz, 1H), 8.47 (dt, J = 6.8, 1.8 Hz, 1H), 8.16 (dd, J = 8.1, 1.4 Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.81 (ddd, J = 8.5, 6.9, 1.6 Hz, 1H), 7.52 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 7.49 – 7.31 (m, 2H), 4.76 (q, J = 7.1 Hz, 2H), 1.57 (t, J = 7.1 Hz, 3H).

¹³C NMR (101 MHz, Chloroform-d) δ 166.8, 158.6, 151.5, 140.0, 134.5, 133.6, 130.3, 129.6, 128.5, 127.8, 126.6, 126.6, 123.5, 115.4, 63.0, 14.4.

2-(3-bromophenyl)-4-ethoxyquinazoline (3oa)²



23.3 mg (71%); off-white solid; mp = 109.3-113.1°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.23 (ddd, J = 8.2, 1.5, 0.7 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.95 – 7.77 (m, 2H), 7.71 (dd, J = 8.0, 1.1 Hz, 1H), 7.59 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 7.44 (td, J = 7.5, 1.2 Hz, 1H), 7.29 (ddd, J = 8.0, 7.4, 1.8 Hz, 1H), 4.73 (q, J = 7.1 Hz, 2H), 1.54 (t, J

= 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.6, 161.9, 151.2, 140.2, 133.7, 133.7, 131.6, 130.2, 127.8, 127.4, 127.0, 123.6, 121.9, 115.1, 63.4, 14.5.

4-ethoxy-2-(naphthalen-2-yl)quinazoline (3pa)²



26.4 mg (88%); off-white solid; mp = $109.3-113.1^{\circ}$ C; ¹H NMR (400 MHz, Chloroform-*d*) δ 9.11 (d, J = 1.6 Hz, 1H), 8.71 (dd, J = 8.6, 1.7 Hz, 1H), 8.20 (dd, J = 8.2, 1.4 Hz, 1H), 8.07 – 8.01 (m, 2H), 7.96 (d, J = 8.7 Hz, 1H), 7.92 – 7.87 (m, 1H), 7.83 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.56 - 7.49 (m, 3H), 4.85 (q, J = 7.1 Hz, 2H), 1.62 (t, J

= 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-d) δ 166.7, 160.1, 151.8, 135.6, 134.7, 133.5, 133.3, 129.2, 128.7, 128.0, 127.8, 127.7, 126.9, 126.4, 126.1, 125.5, 123.6, 115.4, 63.0, 14.5.

4-ethoxy-2-(thiophen-2-yl)quinazoline (3qa)²



21.5 mg (84%); off-white solid; mp = 109.3-113.1°C; ¹H NMR (400 MHz, Chloroform-*d*) δ 8.24 (dd, J = 3.7, 1.3 Hz, 1H), 8.13 (dd, J = 8.2, 1.4 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.82 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.58 – 7.46 (m, 2H), 7.19 (dd, J = 5.0, 3.7 Hz, 1H), 4.75 (q, J = 7.1 Hz, 2H), 1.57 (t, J = 7.1 Hz, 3H).¹³C NMR (101 MHz, Chloroform-d) δ 166.9, 156.4,

149.8, 142.4, 134.3, 130.8, 130.2, 128.6, 126.6, 126.2, 123.7, 114.9, 63.7, 14.3.

4-ethoxy-2-(furan-2-yl)quinazoline (3ra)²



20.9 mg (87%); off-white solid; mp = $78.1-86.5^{\circ}$ C; ¹H NMR (400 MHz, Chloroform-d) & 8.13 (dd, J = 8.1, 1.5 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.79 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.66 (dd, J = 1.7, 0.9 Hz, 1H), 7.48 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 7.38 (d, J = 3.4 Hz, 1H), 6.57 (dd, J = 3.4, 1.8 Hz, 1H), 4.71 (q, J = 7.1 Hz, 2H), 1.54 (t, J = 7.1 Hz, 3H). ¹³C NMR

(101 MHz, Chloroform-d) δ 166.7, 153.1, 152.6, 151.3, 145.1, 133.7, 127.7, 126.3, 123.6, 115.4, 113.9, 112.0, 63.1, 14.3.

(E)-4-ethoxy-2-styrylquinazoline (3sa)



24.3 mg (88%); off-white solid; mp = 72.1-74.5°C; IR (cm⁻¹) v: 3058, 2979, 1614, 1573, 1325, 1102, 970, 765, 678. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.15 (dd, J = 8.2, 1.4 Hz, 1H), 8.05 (d, J =15.8 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.79 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.66 (dd, *J* = 7.3, 1.7 Hz, 2H), 7.49 (ddd, *J* = 8.2, 6.9, 1.2 Hz, 1H), 7.40 (dd, J = 8.2, 6.5 Hz, 2H), 7.37 – 7.27 (m, 2H), 4.75 (q,

J = 7.1 Hz, 2H), 1.57 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-d) δ 166.2, 160.4, 151.3, 138.2, 136.3, 133.6, 128.9, 128.8, 128.1, 127.7, 127.2, 126.3, 123.7, 115.4, 62.9, 14.4. HRMS: m/z (ESI) calcd. for $[C_{24}H_{21}N_2O+H]^+$: 353.1654 found: 353.1652.

4-ethoxy-2-methylquinazoline (3ta)

OEt

12.7 mg (68%); off-white solid; ¹H NMR (400 MHz, Chloroform-d) δ 8.12 (d, J = 8.1 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.76 (t, J = 7.6 Hz, 1H), 7.46 (t, J = 7.5 Hz, 1H), 4.61 (q, J = 7.1 Hz, 2H), 2.71 (s, 3H), 1.50 (t, J = 7.1 Hz, Me 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 166.5, 163.9, 151.3, 133.3, 126.8, 125.9, 123.4, 114.7, 62.7, 26.5, 14.4. HRMS: m/z (ESI) calcd. for $[C_{11}H_{12}N_2O+Na]^+$: 211.0842,

found: 211.0846.

N-(2-(4-ethoxyquinazolin-2-yl)phenyl)benzamide (4a)^{2d}



26.7 mg (73%); yellow solid; ¹H NMR (400 MHz, Chloroform-d) δ 14.24 (s, 1H), 9.00 (dd, J = 8.5, 1.2 Hz, 1H), 8.75 (dd, J = 8.1, 1.6 Hz, 1H), 8.22 - 8.11 (m, 3H), 7.84 - 7.75 (m, 2H), 7.65 - 7.49 (m, 5H), 7.25 -7.17 (m, 1H), 4.91 - 4.63 (m, 2H), 1.57 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-d) & 166.6, 166.2, 160.8, 149.6, 140.6, 136.6,

134.0, 132.0, 131.7, 131.0, 128.6, 127.9, 127.0, 126.2, 123.8, 123.1, 122.8, 120.8, 114.9, 63.4, 14.4.

2-phenylquinazolin-4(3H)-one (5)³



40.0 mg (90%); white solid; ¹H NMR (400 MHz, Chloroform-d) δ 11.53 (s, 1H), 8.33 (dd, J = 8.0, 1.5 Hz, 1H), 8.29 - 8.21 (m, 2H), 7.89 - 7.76 (m, 2H), 7.59 (p, J = 3.4, 2.8 Hz, 3H), 7.51 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H). ¹³C NMR (101 MHz, Chloroform-d) & 163.7, 151.7, 149.4, 134.9, 132.7, 131.7, 129.1, 128.0, 127.4, 126.8, 126.4, 120.9.

4-chloro-2-phenylquinazoline $(6)^3$



18.3 mg (76%); yellow solid; ¹H NMR (400 MHz, Chloroform-d) δ 8.60 (dd, J = 6.7, 3.0 Hz, 2H), 8.26 (dd, J = 8.4, 1.4 Hz, 1H), 8.10 (d, J = 8.4)Hz, 1H), 7.94 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H), 7.67 (ddd, J = 8.1, 6.8, 1.1 Hz, 1H), 7.53 (dd, J = 5.0, 2.0 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-d) & 162.5, 160.1, 151.9, 136.7, 134.8, 131.1, 128.9, 128.7,

128.6, 128.2, 125.8, 122.5.

6-methyl-5,6-dihydro-8H-isoquinolino[1,2-b]quinazolin-8-one (7)⁴



17.5 mg (67%); white solid; ¹H NMR (400 MHz, Chloroform-d) δ 8.42 (dd, J = 7.7, 1.5 Hz, 1H), 8.27 - 8.19 (m, 1H), 7.68 (dd, J = 6.3, 1.6 Hz, 2H), 7.47 - 7.32 (m, 3H), 7.24 - 7.15 (m, 1H), 5.49 (qd, J = 6.7, 1.8 Hz, 1H), 3.30 (dd, J = 16.0, 5.9 Hz, 1H), 2.83 (dd, J = 16.0, 1.7 Hz, 1H), 1.17 (d, J = 6.7 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-d) δ 161.3, 148.6, 147.8, 134.8, 134.2,

131.9, 129.0, 128.6, 127.9, 127.6, 126.8, 126.5, 120.9, 45.4, 33.6, 18.0.

Reference

- (1) G. D. Ju, G. B. Li, G. W. Qian, J. Y. Zhang and Y. S. Zhao., Org. Lett. 2019, 21, 7333-7336.
- (2) (a) H. Wang, M. M. Lorion, and L. Ackermann. Angew. Chem., Int. Ed., 2016, 55, 10386–10390; (b) J. Wang, S. K. Zha, K. H. Chen, F. F. Zhang, C. Song and J. Zhu. Org. Lett., 2016, 18, 2062–2065; (c) X. M. Wang, A. Lerchen, and F. Glorius. Org. Lett., 2016, 18, 2090–2093; (d) F. Wang, H. Wang, Q. Wang, S. J. Yu and X. W. Li. Org. Lett., 2016, **18**, 1306–1309. (3) X. Y. Wang and N. Jiao. *Org. Lett.*, 2016, **18**, 2150–2153.
- (4) G. Bairy, S. Das, H. M. Begam and R. Jana. Org. Lett. 2018, 20, 7107-7112.

¹H and ¹³C NMR spectra 6















































fl (ppm)























220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 fl (ppm)













